[The male breast carcinoma: a center experience].
Male breast carcinoma represents a rare tumor entity and is not the focus of major research activities although an increasing incidence has to be noticed. Registry data on 67 males diagnosed and treated for breast carcinoma during the period 1985-2005 in the metropolitan area of Leipzig were retrospectively analyzed. The median age at diagnosis was 65 years (39-92 years) with an incidence peak in the age group 60-70 years. According to the TNM classification a carcinoma in situ was diagnosed in 8 % (n = 5) of the cases and an invasive carcinoma T1 in 39 % (n = 26 ), T2 in 38 % (n = 25), T3 (n = 0) and T4 in 15 % (n = 11). The lymphnode status presented in 56 % negative and in 44 % positive (N1 + N2) nodes. Solid organ metastasis was detected in only 6 % of the patients. The overall 5-year survival is 72 % and comparable with published data. Respective survival rates for patients diagnosed with UICC-stadium 1-4 are 81 %, 76 %, 65 % and 0 %. These rates are similar to those of female patients. Considering the low incidence of male breast carcinoma and the limited knowledge on this rare disease surgeons should apply diagnostic and therapeutic guidelines that are established for the treatment of female breast carcinoma unless powerful evidence based data will become available.